Axiron

Axiron is a brand name of testosterone, approved by the FDA in the following formulation(s):

AXIRON (testosterone - solution, metered; transdermal)

• 
  Manufacturer: ELI LILLY AND CO
  
  Approval date: November 23, 2010
  
  Strength(s): 30MG/1.5ML ACTIVATION ^[RLD]

Has a generic version of Axiron been approved?

No. There is currently no therapeutically equivalent version of Axiron available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Axiron. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Dermal penetration enhancers and drug delivery systems involving same
  Patent 6,299,900
  Issued: October 9, 2001
  Inventor(s): Reed; Barry Leonard & Morgan; Timothy Matthias & Finnin; Barrie Charles
  Assignee(s): Monash University
  A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
  
  Patent expiration dates:
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
    ✓ 
    Drug product
  
  



• 
  Dermal penetration enhancers and drug delivery systems involving same
  Patent 6,818,226
  Issued: November 16, 2004
  Inventor(s): Barry Leonard; Reed & Timothy Matthias; Morgan & Barrie Charles; Finnin
  Assignee(s): ACRUX DDS Pty. Ltd.
  A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
  
  Patent expiration dates:
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
    ✓ 
    Drug product
  
  



• 
  Transdermal delivery of hormones
  Patent 6,923,983
  Issued: August 2, 2005
  Inventor(s): Morgan; Timothy Matthias & Bakalova; Margarita Vladislavova & Klose; Karthryn Traci-Jane & Finnin; Barrie Charles & Reed; Barry Leonard
  Assignee(s): Acrux DDS PTY LTD
  The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention
  
  Patent expiration dates:
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
    ✓ 
    Drug product
  
  



• 
  Dermal penetration enhancers and drug delivery systems involving the same
  Patent 8,071,075
  Issued: December 6, 2011
  Inventor(s): Reed; Barry Leonard & Morgan; Timothy Matthias & Finnin; Barrie Charles
  Assignee(s): Acrux DDS Pty Ltd.
  The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.
  
  Patent expiration dates:
  
  
  • February 19, 2017
    
    ✓ 
    Patent use: TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 23, 2013 - NEW PRODUCT
  
  

See also...

• Axiron Consumer Information (Drugs.com)
• Axiron Solution Consumer Information (Wolters Kluwer)
• Axiron Consumer Information (Cerner Multum)
• Axiron Advanced Consumer Information (Micromedex)
• Testosterone Consumer Information (Drugs.com)
• Testosterone Consumer Information (Wolters Kluwer)
• Testosterone Gel Consumer Information (Wolters Kluwer)
• Testosterone Patch Consumer Information (Wolters Kluwer)
• Testosterone Solution Consumer Information (Wolters Kluwer)
• Testosterone buccal system Consumer Information (Cerner Multum)
• Testosterone injection Consumer Information (Cerner Multum)
• Testosterone topical Consumer Information (Cerner Multum)
• Androplex Advanced Consumer Information (Micromedex)
• Testosterone Buccal Advanced Consumer Information (Micromedex)
• Testosterone Topical application Advanced Consumer Information (Micromedex)
• Testosterone Transdermal Advanced Consumer Information (Micromedex)
• Testosterone AHFS DI Monographs (ASHP)